CD274 and prostate carcinoma: In spite of preclinical rationale for dual blockade of PD-1/PD-L1 in prostate cancer, no objective responses were seen in the prostate cancer cohorts in phase I PD-1 and PD-L1 trials [98–101] (Table 2).